Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Current Assets (2016 - 2026)

Amphastar Pharmaceuticals has reported Current Assets over the past 13 years, most recently at $636.0 million for Q4 2025.

  • For Q4 2025, Current Assets rose 19.09% year-over-year to $636.0 million; the TTM value through Dec 2025 reached $636.0 million, up 19.09%, while the annual FY2025 figure was $636.0 million, 19.09% up from the prior year.
  • Current Assets for Q4 2025 was $636.0 million at Amphastar Pharmaceuticals, down from $639.5 million in the prior quarter.
  • Over five years, Current Assets peaked at $639.5 million in Q3 2025 and troughed at $300.2 million in Q1 2021.
  • A 5-year average of $456.2 million and a median of $445.2 million in 2023 define the central range for Current Assets.
  • Biggest five-year swings in Current Assets: skyrocketed 41.33% in 2023 and later increased 0.54% in 2024.
  • Year by year, Current Assets stood at $318.1 million in 2021, then rose by 18.92% to $378.3 million in 2022, then increased by 29.41% to $489.6 million in 2023, then rose by 9.08% to $534.1 million in 2024, then increased by 19.09% to $636.0 million in 2025.
  • Business Quant data shows Current Assets for AMPH at $636.0 million in Q4 2025, $639.5 million in Q3 2025, and $580.8 million in Q2 2025.